Aim: The present study was designed to conduct a pharmacokinetic study for developed flurbiprofen press coated pulsatile release tablets (PRT), which are intended to treat early morning surge in rheumatoid arthritis. Settings and Design: A simple, accurate, specific and Linear reverse phase high-performance liquid chromatography method has been developed and validated for the estimation of Flurbiprofen in rabbit plasma. The formulated tablets were tested in vivo in New Zealand white male rabbits for various pharmacokinetic parameters.
INTRODUCTION
O ral formulations of flurbiprofen are indicated for the acute or long-term symptomatic treatment of rheumatoid arthritis (RA), osteoarthritis and ankylosing spondylitis. Flurbiprofen is a nonsteroidal antiinflammatory agent, a propionic acid derivative with antipyretic and analgesic activity. [1] The anti-inflammatory effect of flurbiprofen occurs through reversible inhibition of cyclooxygenase, the enzyme responsible for the conversion of arachidonic acid to prostaglandin G2 (PGG2) and PGG2 to PGH2 in the prostaglandin synthesis pathway. [2] This effectively decreases the concentration of prostaglandins involved in inflammation, pain, and swelling.
RA is a long-term autoimmune disorder that primarily affects joints. RA typically manifests with signs of inflammation, with the affected joints being swollen, warm, painful and stiff, particularly early in the morning on waking or following prolonged inactivity. [3] Increased stiffness early in the morning is often a prominent feature of the disease and typically lasts for more than an hour. [4] RA requires time-dependent drug
ORIGINAL ARTICLE
release for maximum therapeutic benefit. [5] Development of pulsatile tablets is one of the promising time specific systems that release the drug after a predetermined lag time for treating this disease condition occurring in the early hours. [6] In the literature survey carried out, there were only few estimation procedures of flurbiprofen in rabbit plasma, [7] [8] [9] therefore, an attempt was made to develop and validate a simple, accurate, precise, selective reverse phase high performance liquid chromatography (RP-HPLC) method for determination of flurbiprofen in rabbit plasma so that it was used further in carrying out the pharmacokinetic study.
MATERIALS AND METHODS

Materials and instruments
Flurbiprofen, Explotab, Methocel LV Premium E50, and Ibuprofen were gift samples from Hetero drugs, Hyderabad, India. All other chemicals used were of analytical and HPLC grade procured from S.D. Fine chemicals (Make: Merck and Fisher Scientific). Shimadzu LC 2010CHT HPLC was used along with Lab solutions Software with column waters symmetry.
Analytical method for estimation of flurbiprofen
The analysis of flurbiprofen was done by Shimadzu LC 2010CHT HPLC which was used along with Lab solutions Software with column waters symmetry. The chromatographic separation was performed by phenomenex Gemini C18 (250.0 × 4.6 mm, 5 µ). The mobile phase consisted of 10 mm potassium dihydrogen phosphate (KH2PO4) buffer and acetonitrile buffer (pH 4.0 ± 0.2) with a volumetric ratio of 55: 45 at a flow rate of 1.0 ml/min. The UV detector was set at 245 nm, and injection volume was 20 µL. The calibration curve was generated for concentrations ranging from 0.5 to 75.0 µg/ml. Mobile phase gave good separation of main peak, diluent, plasma peak, and internal standard peak. Efficiency and asymmetry were also within the acceptance criteria. The resolution between main peak and internal standard was more than 2.0.
Preparation of mobile phase
1.36 g of potassium monobasic phosphate was accurately weighed and transferred into 1000 ml of water, to it 1 ml of triethylamine was added, and pH of the solution was adjusted to 4.0 ± 0.05 using diluted orthophosphoric acid, the solution was filtered through 0.45 um filter paper (PVDF membrane filter, make: Millipore). Further, 550 ml of buffer was mixed with 450 ml of acetonitrile and degassed by sonication to acquire a volumetric ratio of 55:45.
Preparation standard solution
Stock solution was prepared by weighing 50 mg of flurbiprofen in 100 ml of mobile phase. The internal standard stock solution was prepared by weighing 50 mg of ibuprofen in 100 ml of mobile phase. Each 5 ml of above solutions were pipetted out separately transferred into 50 ml volumetric flask than the volume was makeup to achieve 50 ml (50 µg/ml) using mobile phase.
Sample solution
The plasma sample was previously extracted using liquid -liquid extraction in a 10 ml volumetric flask to which 1 ml internal standard was added and mobile phase was used to make up the rest volume, after thorough mixing the solution was transferred into centrifuge tube and centrifuged at 3000 rpm for 5 min and the clear supernatant was collected and analyzed.
System suitability and precision
The system suitability is done by taking the area of standard preparation for five replicas to verify the working of the analytical system used. It should meet system suitability criteria. [10] The precision of an analytical method is the degree of agreement among individual test results when the method is applied repeatedly to multiple sampling of a homogeneous sample.
The precision of the analytical method is usually expressed as the standard deviation or relative standard deviation (coefficient of variation) of series of measurements. The system suitability parameter was carried out at 100% standard solution (50 µg/ml).
Linearity
The linearity of an analytical method is its ability to elicit test results that are directly or by a well-defined mathematical transformation, proportional to the concentration of an analyte in samples within a given range. To demonstrate linearity of the test method, five standard solutions with concentration ranging from 10% to 150% of test concentration were prepared by spiking standard stock solution.
Specificity
Specificity of an analytical method is its ability to measure accurately and specifically the analyte of interest without interferences from blank and plasma. Plasma and diluent were injected into HPLC system, and interference was compared by direct comparison method.
Limit of quantification (LOQ)
The quantification limit of an individual analytical procedure is the lowest amount of analyte in a sample that can be quantitatively determined with suitable precision, accuracy, respectively. It can be determined by S/N ratio or by linearity. LOQ is calculated by the standard deviation of response and the slope from 10% to 150% of linearity. The required dilutions were prepared, each in triplicate for calculating LOQ. LOQ = 10 σ/S; where σ is the standard deviation of the lowest standard concentration and S is the slope of the standard curve. [11] 
Method precision
In method precision, a homogeneous sample of a single batch is analyzed for 6 times. This indicates whether a method gives consistent results or not for a single batch. The obtained results are tabulated.
Accuracy and recovery
The accuracy of an analytical procedure expresses the closeness of agreement between the value which is accepted either as a conventional true value or an accepted reference value and the value found.
Recovery of flurbiprofen was estimated with various concentrations ranging from 50% to 150% of target concentration (0.025 mg/ml) by spiking the standard drug solution. Recovery was conducted in triplicate preparation at 50%, 100%, and 150% level. The samples were centrifuged at 3000 rpm for 10 min. The supernatant was separated and injected into HPLC system.
Robustness
The robustness is determined by varying the flow rate from 0.9 ml/min to 1.1 ml/min. The prepared standard solution of flurbiprofen was injected by varying the flow rate from 0.9 ml/min to 1.1 ml/min along with the optimized method.
Pharmacokinetic studies
In vivo pharmacokinetic studies were conducted in New Zealand white male rabbits weighing 2.5-3 kg, by following all ethical guidelines for investigations in laboratory animals, which was approved by the Institutional Animal Ethical Committee. (1505/PO/a/11 CPCSEA). The study was carried out to compare the pharmacokinetics of optimized pulsatile release tablets (PRT) and rapid release core tablet (RRT) of flurbiprofen. The precompression parameters of the powder blend of the tablets, the preparation methods, various physical evaluation tests and in vitro drug release studies including their lag time are completely discussed in Reddy et al. [12] (development and characterization of press coated tablet of flurbiprofen: A chronotherapeutic approach. Asian Journal of Pharmaceutics) from that study the optimized RRT and PRT were selected for the pharmacokinetic study. The overnight fasted male New Zealand white rabbits were divided into 2 groups (n =6) and treated orally with RRT's and PRTs, respectively. Tablets were administered orally by the help of a gastric intubation tube. [13] After oral administration of tablets 1 ml of blood sample was collected at each time point 30 min, 1 hr, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 hrs from the marginal ear vein of the rabbit. Rabbits were held in rabbit restainers during blood sampling. The blood was collected into tubes containing ethylenediamine tetraacetic acid. The plasma was separated immediately at 10000 rpm for 10 min using cold centrifugation and stored at −20°C until future analysis. The above discussed method was opted for the preparation of HPLC plasma samples and injected into HPLC system and detected by UV detector at 245 nm for the content of flurbiprofen in the formulated tablets.
RESULTS AND DISCUSSION
The aim of this work was focused on to develop and validate a simple, precise RP-HPLC method for estimation of flurbiprofen in formulated dosage forms. Different mobile phases such as acetonitrile and sodium dihydrogen phosphate, acetonitrile and potassium dihydrogen orthophosphate were used in different compositions with different flow rates but peak resolution, tailing factor, retention time were not satisfactory. Finally, potassium dihydrogen phosphate (KH2PO4) buffer and acetonitrile (pH 4.0 ± 0.2) with a volumetric ratio of 55:45 at a flow rate of 1.0 ml/min was selected. The chromatographic separation was done using Phenomenex Gemini C18 column (250.0 × 4.6 mm, 5 µ) with a flow rate of 1 ml/min with a run time of 10 min, at 245 nm [ Figure 1 ].
System suitability and linearity
The system suitability tests were conducted before performing the validation, and the parameters were within the acceptance criteria like % relative standard deviations (RSD) of peak areas of 6 injections were ≤2%, theoretical plate count was >2000, and peak tailing was <2 [ Table 1 ]. Hence, the proposed system is precise and suitable for further analysis. The linearity range of flurbiprofen was in the range of 5-75 µg/ml with a linear regression equation y (flurbiprofen) = 9206x + 5939 (r 2 = 0.999) [ Figure 2 and Table 2 ]. 
Specificity, LOQ and precision
When plasma and diluent were injected into HPLC system, no interference was observed from the diluent and plasma peaks at the retention time of standard and internal standard peaks [ Figure 3 ]. LOQ of flurbiprofen was calculated using slope and Y-intercept from concentrations ranging 0.5-75 µg/ml, and it was found to be 3 µg/mL from the linearity (calibration curve) [ Table 3 and Figure 4 ]. Furthermore, the S/N ratio was satisfactory 15 from 1 µg/ml. Six replicates injections of same concentration were analyzed in the precision, and the % RSD of flurbiprofen were within acceptable limits. Hence, the method was precise [ Table 4 ].
Recovery
The percentage recoveries of flurbiprofen from various samples analyzed were found to be between 97.7% and 100.4%. The results of the recovery studies undoubtedly demonstrate the accuracy of the proposed method [ Table 5 and Figure 5 ].
Robustness
Robustness of the proposed method demonstrated a nonsignificant alteration through analysis of the sample. It was confirmed that by the deliberate changes in the flow rate parameters there was no significant changes in % RSD, theoretical plates and tailing factor [ Table 6 ].
Pharmacokinetic studies
The developed method was successfully applied for pharmacokinetic study in the New Zealand Rabbits and the results are as follows. In case of RRT flurbiprofen was detected within 30 min after its oral administration in rabbits whereas it was more than 5 h in PRT which clearly indicated that there was a predominant lag time before the drug release. The absorption of drug was rapid in case of RRT's, i.e., a C max of 54.2 ± 2.18 µg/ml −1 was attained at a T max of 2 h. In PRT's a C max of 45.10±9.71 µg ml −1 was attained at a T max of 8 h, no drug was detected till the end of 4 th h in all the six rabbits, indicated same absorption pattern as PRT's but after a lag time. The other pharmacokinetic parameters determined are AUC (0-∞) 352.86 µg ml −1 h −1 , elimination rate constant 0.052 h −1 and half-life of 13.32 h for RRT's. Similarly, for PRT's they were AUC (0-∞) 324.21 µg ml −1 h −1 , elimination rate constant 0.047 h −1 and half-life of 14.74 h. From the above results, it was clear that there was no major difference in the pharmacokinetic parameters of PRT's and RRT's.
The results of the in vivo bioavailability test indicated that drug release from a pulsatile tablet is similar to that of RRT thereby providing prolonged and desired lag time [ Figure 6 ]. 
